📰 Pascal Nigen News
Pascal Nigen News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pascal Nigen. Real-time updates on events, politics, business and more.
October 3, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / October 3, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and
September 27, 2022
Statistically significant results with Quilience® (Mazindol ER) achieving a 7.1 point mean reduction in ESS from baseline compared to a 3.2 point reduction for placebo, p=0.0081Fast onset of action from
September 19, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / September 19, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP), (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery
September 8, 2022
Company also announces expected departure of Sylvia Panigone, Ph.D.ZURICH, SWITZERLAND / ACCESSWIRE / September 8, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage
June 10, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery
June 6, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery
June 2, 2022
Press release content from Accesswire. The AP news staff was not involved in its creation.
June 2, 2022
60-patient enrollment target met plus 12% over-enrollment; top-line Phase 2a results expected to be presented during the European Sleep Research Society Congress in September 2022Nearly 90% of patients
May 4, 2022
Since the interim results were released in March, patient enrollment has nearly doubledOf the 60 patients planned for the study, 54 have now been randomized with several others currently undergoing screeningNearly
April 22, 2022
ZURICH, SWITZERLAND / ACCESSWIRE / April 22, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development